Vaccines

From its results, the company plans to file a Biologics License Application (BLA) with the FDA.

If granted the Emergency Use Authorization (EUA), this vaccine would be available for individuals 18 years and older.

Read this week’s top infectious disease stories you may have missed, including Dr. Anthony Fauci’s announcement.

People who initially received an mRNA vaccine but were boosted with the Janssen vaccine had superior immune responses, the study found.

If it is granted an Emergency Use Authorization (EUA), the vaccine could be used as a booster dose for individuals 18 years and older vaccinated with any of the other available COVID-19 vaccines.

Investigators sought to address the effectiveness of vaccination after COVID-19 recovery.

Neutralization of BA.4 and BA.5 dropped significantly for individuals who were infected with a previous strain of Omicron, even if they were also vaccinated.

The agency decided to allow for intradermal injection thus increasing the number of available doses substantially.

The company and its partner, Pfizer, are preparing for the potential launch of 2 variant-adapted bivalent COVID-19 vaccines assuming authorizations from FDA and EMA.

A new study finds there are more pharmacies than physician practices in these areas; however, these inequities offer an opportunity for pharmacists to step-in and provide vaccine education and administration.

Omicron-specific vaccine boosters are coming, but just how necessary are they?

The highest rate of myocarditis or pericarditis after mRNA COVID-19 vaccination occurred among young men ages 18 to 24 after receiving a second dose of the Moderna vaccine.

The model suggests screening unvaccinated students could reduce absences by 80% compared to reactively closing classes with infected students.

Prior infection is not enough: COVID-19 vaccination reduces the risk of reinfection by 50%.

This Israeli study found 3 and 4 doses of Pfizer-BioNTech bolstered antibody titers in adults 60 and older.

A specific immunization marker showed the percentage of children receiving common vaccines fell 5% between 2019 and 2021.

In children 5-11 years old, 2 doses of the Pfizer-BioNTech COVID-19 vaccine were moderately effective against documented, symptomatic Omicron infection.

Predicted time to breakthrough infection after mRNA vaccination was significantly longer than the time to breakthrough infection after natural infection or after viral vector vaccination.

The European agency says there have been “a few cases of anaphylaxis.” The label will also include warnings for paraesthesia and hypoaesthesia.

Children and adolescents previously infected with COVID-19 or MIS-C demonstrated insufficient antibody titers and neutralization capability against the Omicron variant.

There has been an increase in transmission rates, the release of new White House strategies to address BA.5, and new potential offerings to prevent and treat the virus.

The federal agency says it is indicated as a two-dose primary series for active immunization to prevent the virus in individuals 18 years of age and over.

At 12 months after COVID-19 infection, anti-SARS-CoV-2 spike receptor-binding domain IgG persisted in all age groups.

Receiving a COVID-19 booster vaccine significantly reduced Omicron infections among National Basketball Association (NBA) players and staff.

Omicron significantly diminishes the protective abilities of both natural immunity and vaccine-granted immunity.